# PROSINT (NCT02570919)

> Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: intermediate-risk prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02570919
- Phase: NA
- Status: COMPLETED
- Sponsor: Fundacao Champalimaud
- Conditions: PROSTATE CANCER
- Interventions: IGRT 45 Gy in 5 fractions of 9 Gy; IGRT 24 Gy single dose
- Enrollment: 30
- Primary outcome: Number of patients with treatment-related adverse events as assessed by Common Toxicity Criteria for Adverse Effects v4.0

## Indexed commentary on PROSINT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=prosint-nct02570919